Key result
Lower plasma miR-143 and miR-145 levels strongly predict in-stent restenosis after PCI.
Why the study?
In-stent restenosis remains a major problem in the DES era, and the potential of plasma microRNAs implicated in vascular smooth muscle cell phenotypic switching to serve as noninvasive biomarkers for ISR required investigation.
Do plasma levels of miR-21, miR-143, and miR-145 serve as accurate noninvasive biomarkers to identify in-stent restenosis in patients 6 to 12 months after drug-eluting stent implantation?
Case-Control (n=209)
Do plasma levels of miR-21, miR-143, and miR-145 serve as accurate noninvasive biomarkers to identify in-stent restenosis in patients 6 to 12 months after drug-eluting stent implantation?
Answers are grounded in this paper and cite their sources.
Decreased plasma levels of miR-143 and miR-145 demonstrate high diagnostic accuracy (AUCs of 0.839 and 0.871) as potential noninvasive biomarkers for detecting in-stent restenosis after drug-eluting stent implantation.
Objective In-stent restenosis (ISR) remains a major problem even in the drug-eluting stent (DES) era, and the mechanism of ISR was neointimal growth. MicroRNAs (miRNAs) regulate the formation of pathologic vascular neointimal lesion. Therefore we investigated the levels of plasma miRNAs that specifically implicated in vascular smooth muscle cell phenotypic switching in patients with ISR and determined the potential of the miRNAs to serve as biomarkers for ISR. Methods Two hundred and nine patients, who received coronary angiography six months to one year after first PCI (for drug-eluting stent implantation), were divided into ISR (n=62) and Non-ISR (Control, Ctl) (n=147) group according to the chromatography results. Plasma miR-21, miR-143, miR-145, miR-221 and miR-222 levels were determined by quantitative real-time PCR. Receiver operating characteristic curves analysis was used to evaluate the diagnostic ability of miR-21, miR-143 and miR-145. Results The relative quantity expression of miR-21 was significantly higher in plasma from ISR patients than that from Ctl patients (p=0.001), while the levels of miR-143 (p=0.0001) and miR-145 were significantly decreased in plasma from ISR patients compared with Ctl patients (p<0.0001). The plasma levels of miR-221 (p>0.05) and miR-222 (p>0.05) had no significance between two groups. The area under curve of miR-21, miR-143 and miR-145 was 0.564 (p<0.01), 0.839(p<0.001) and 0.871 (p<0.001). The specificity of them was 85%, 93.5%, and 95.1%. The sensitivity of them was 42.1%, 73.7% and 75.7%. Conclusions Plasma miR-143 and miR-145 can be used as potential molecular markers of ISR. The levels of miR-21, miR-143 and miR-145 in plasma may be a new therapeutic target for ISR.
No takes yet. Share an insight, caveat, or question.
He et al. (2011) conducted a case-control in In-stent restenosis after drug-eluting stent implantation (n=209). Plasma miR-143 and miR-145 levels (along with miR-21, miR-221, miR-222) vs. Non-ISR control group (n=147) was evaluated on Diagnostic ability for in-stent restenosis (ISR) evaluated by ROC curve (AUC) (AUC 0.839 (miR-143); AUC 0.871 (miR-145), p=<0.001). Plasma miR-143 and miR-145 levels were lower in ISR patients and predicted ISR with AUCs of 0.839 and 0.871.
Synapse has enriched 10 related papers. Consider them for comparative context: